Avinger To Reveal CONNECT II Clinical Trial Results for First-Ever Imaging CTO Catheter To Help Save PAD Patients’ Legs
Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for treating patients with Peripheral Artery Disease (PAD), announces it will reveal its CONNECT II global clinical trial results at the Vascular Interventional Advances (VIVA) Conference 2012 in Las Vegas, Nevada, October 9-12, 2012.
CONNECT II is a global clinical study that evaluated the safety and efficacy of Ocelot , the first-ever interventional Chronic Total Occlusion (CTO) crossing catheter to incorporate Optical Coherence Tomography, or OCT. This technology is used to image inside the artery, allowing physicians to navigate, see, and cross totally blocked arteries in the legs of patients suffering from PAD.
PAD is a silent, unsung pandemic that affects approximately 18 million adults in the U.S., 30 million globally and is the leading cause of amputation in patients over 50. According to the American Heart Association journal Circulation, it afflicts even more women than men.
Final results will be revealed by Interventional Cardiologist Dr. Matt Selmon, CONNECT II Co-Principal Investigator of Heart Hospital of Austin. The venue will be the Late Breaking Clinical Trial session in the Wynn Hotel on Thursday, October 11, 2012 at 1:50 p.m. PT. Avinger representatives will also be at VIVA Booth #320 throughout the week.
To learn more about PAD, visit http://avinger.com/patients.
Founded in 2007 by renowned cardiologist and medical device entrepreneur Dr. John B. Simpson, Avinger develops next-generation catheter-based technologies for the treatment of peripheral artery disease (PAD). Leveraging core competencies in medical device catheter engineering and intravascular Optical Coherence Tomography (OCT), Avinger markets Wildcat and Kittycat catheters, and received CE Mark in 2011 to market Ocelot , the first ever real-time OCT crossing catheter. www.avinger.com .